Clinical Trials Logo

Clinical Trial Details — Status: Available

Administrative data

NCT number NCT04074512
Other study ID # CYP-001
Secondary ID
Status Available
Phase
First received
Last updated

Study information

Verified date April 2024
Source Sentynl Therapeutics, Inc.
Contact Sentynl Therapeutics Study Team
Phone 888-507-5206
Email studyinfo@sentynl.com
Is FDA regulated No
Health authority
Study type Expanded Access

Clinical Trial Summary

This study investigates the clinical effects and safety of subcutaneous Copper Histidinate treatment for newly diagnosed Menkes disease patients under 6 years of age.


Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Copper Histidinate
Restoring Copper Histidinate levels normally found in the blood to assist in the maintenance of copper homeostasis.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sentynl Therapeutics, Inc.
See also
  Status Clinical Trial Phase
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Recruiting NCT04977388 - NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome Phase 1/Phase 2
Completed NCT00811785 - Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency Phase 3
Enrolling by invitation NCT04337684 - Long Term Follow-up on Menkes Disease Patients

External Links